RxDoctor Payments Data

Suzanne Brown, PA

Medical · Elkins, WVNPI 1487673372

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 182 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 27.0% of the total.

$3,154in general payments, 2019–2025

Across 182 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$851
  • Novartis$434
  • AstraZeneca$312
  • Amgen$275
  • Merck$215
  • Philips North America LLC$212
  • plus $857 from 10 others

What the payments were for

  • Food & beverage$3,154100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,154 in reported general payments places this provider in the 80th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$29,771
Medicare patients
257
Services billed
340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$150,285
XareltoRivaroxaban51$64,950
BrilintaTicagrelor44$45,156
EntrestoSacubitril/Valsartan37$37,322
Repatha SureclickEvolocumab28$36,789
Ranolazine ErRanolazine29$2,680
Amiodarone Hcl36$2,319
Metoprolol Succinate173$2,224
Isosorbide Mononitrate ErIsosorbide Mononitrate178$2,214
Flecainide Acetate37$2,099
Nitroglycerin PatchNitroglycerin28$1,459
ClopidogrelClopidogrel Bisulfate147$1,367
Rosuvastatin Calcium114$972
Atorvastatin Calcium106$776
Ezetimibe36$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$210$150,285109 claims
Johnson & JohnsonXarelto$102$64,95051 claims
AstraZenecaBrilinta$312$45,15644 claims
NovartisEntresto$434$37,32237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 medical providers in West Virginia.

Other medical in Elkins

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →